Brief: Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
04/06/2024 14:17
June 4 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA ANNOUNCES NEW ANALYSES OF PHASE
2 ORAGROWTH212
TRIAL PRESENTED AT ENDO 2024
Source text for Eikon: ID:nGNX6FMJv0
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)